Quidel and Life Technologies Receive FDA Clearance for Clostridium difficile Assay and QuantStudio™ Dx and 7500 Fast Dx Real

 Quidel and Life Technologies Receive FDA Clearance for Clostridium difficile
     Assay and QuantStudio™ Dx and 7500 Fast Dx Real-Time PCR Instruments

FDA issues 510(k) Clearance for Quidel Molecular Direct Clostridium difficile
Assay and Life Technologies Real-Time PCR Instruments for Monitoring
Hospital-Acquired Infections

PR Newswire

SAN DIEGO and CARLSBAD, Calif., March 18, 2013

SAN DIEGO and CARLSBAD, Calif., March 18, 2013 /PRNewswire/ --Quidel
Corporation (NASDAQ: QDEL) and Life Technologies Corporation (NASDAQ: LIFE)
announced today that they received 510(k) clearances from the United States
Food and Drug Administration (FDA) to market the Quidel Molecular Direct C.
difficile Assay with Life Technologies' QuantStudio™ Dx and 7500 Fast Dx
Applied Biosystems® Real-Time PCR Instruments.

(Photo: http://photos.prnewswire.com/prnh/20130318/LA78485)

Clostridium difficile bacterial infections are life-threatening, especially
for the elderly, immunocompromised populations, and for patients on a
prolonged antibiotic regimen. C. difficileinfection (CDI) is frequently
associated with antibiotic therapy and extended hospital stays.

"According to The Centers for Disease Control and Prevention (CDC), 14,000
deaths are attributed to CDI in the U.S. each year, which costs the national
healthcare system about $1 billion in excess treatment. For this reason, a
fast and accurate diagnosis is vital to the patient's proper treatment and
speedy recovery,"^1 said Douglas Bryant, president and chief executive officer
for Quidel Corporation, who added, "With the clearance of our C. difficile
assay, we extend our Quidel Molecular product line beyond respiratory
infections with products that address the needs of hospital laboratories in
higher-volume settings."

"Molecular diagnostic assays have become the gold standard for infectious
disease testing in the clinical lab," said Ronnie Andrews, president of
medical sciences at Life Technologies. "Molecular testing is the
fastest-growing segment of the diagnostics market, and Life Technologies' deep
expertise in real-time PCR instrumentation, together with our demonstrated
effectiveness in pursuing regulatory pathways for our instruments, uniquely
positions Life to become a leader in the diagnostics market."

This Quidel Molecular Direct C. difficile Assay is part of Quidel's expanding
line of molecular diagnostics products. The Quidel Molecular product line
offers PCR reagent kits for use by molecular diagnostic laboratories,
including Life Technologies' QuantStudio™ Dx and 7500 Fast Dx. These reagents
provide attractive features that include refrigerated storage instead of
freezing, convenient ready-to-use reagents, a short time to result, and other
benefits that favorably enhance the molecular workflow.

The Quidel Molecular Direct C. difficile Assay kit includes an
extraction-free, three-step sample preparation process that requires no heat
step, no timed step, and no centrifugation as an added benefit. This fast and
easy direct-to-amplification procedure allows the assay to generate a result
in less than 70 minutes by an efficient and economical method.

"Combining multiple system capabilities in a single footprint, the
QuantStudio™ Dx is our flagship instrument in the diagnostic lab market," said
Andrews. "Life Technologies is committed to providing physicians and clinical
laboratories with instrumentation designed for flexibility and ease of use, as
well as best-in-class diagnostic tests where we see unmet clinical need."

The QuantStudio™ Dx Real-Time PCR instrument's touch screen, reagent and
sample tracking, and LIMS (Laboratory Information Management Systems)
interface are specifically designed for ease of use, and the six-color feature
allows for a multiplex of six targets in one reaction.

The 7500 Fast Dx Real-time PCR Instrument system is a five-color real-time PCR
instrument that delivers the performance required for high-quality results in
a 96-well format. The 7500 Fast Dx is also FDA cleared for diagnostic use with
the Center for Disease Control's H1N1 assay and with the Quidel Molecular
assays for Influenza A+B and human metapneumovirus (hMPV).

With the QuantStudio™ Dx, flexibility is enabled through an optional Test
Development mode allowing the use of easily interchangeable thermal cycling
blocks that accommodate 96- or 384-well plates and a proprietary qPCR
microfluidics card, which can perform 48 tests on eight samples simultaneously
without the need for liquid-handling robots. The card can also be used to
design and implement custom tests. Life Technologies is currently developing
diagnostic tests utilizing this format. In this Test Development mode, the
QuantStudio™ Dx can perform numerous functions, including pathogen detection,
gene expression analysis, SNP genotyping, copy number analysis, mutation
detection, micro-RNA and other non-coding RNA analysis, and high-resolution
melt analysis.

The current 510(k) clearance represents another milestone in the extension of
Life Technologies' move into the diagnostics arena. In September 2012, Life
Technologies launched Pervenio™ Lung RS, a lab-developed test distinguishing
high-risk from low-risk early stage lung cancer patients. In February 2013,
the company received 510(k) clearance for its 3500 Dx Genetic Analyzers and
SeCore® HLA typing kits.

The Quidel Molecular Direct C. difficile Assay is Quidel's first assay with a
streamlined stool processing procedure. Quidel also sells FDA approved
molecular tests in the Real-Time PCR format for Influenza A+B, hMPV and RSV +

1. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6109a3.htm?s_cid=mm6109a3_w

About Life Technologies

Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people
around the globe through the development of diagnostic solutions that can lead
to improved patient outcomes and provide economic benefits to the healthcare
system. Marketed under the QuickVue®, D3® Direct Detection and Thyretain®
leading brand names, as well as under the new Sofia® and AmpliVue® brands,
Quidel's products aid in the detection and diagnosis of many critical diseases
and conditions, including, among others, influenza, respiratory syncytial
virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood.
Quidel's research and development engine is also developing a continuum of
diagnostic solutions from advanced lateral-flow and direct fluorescent
antibody to molecular diagnostic tests to further improve the quality of
healthcare in physicians' offices and hospital and reference laboratories. For
more information about Quidel's comprehensive product portfolio, visit
www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made byLife Technologies with the Securities and Exchange
Commission.Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.

Quidel Forward-Looking Statement

This press release contains forward-looking statements within the meaning of
the federal securities laws that involve material risks, assumptions and
uncertainties. Many possible events or factors could affect our future
financial results and performance, such that our actual results and
performance may differ materially from those that may be described or implied
in the forward-looking statements. As such, no forward-looking statement can
be guaranteed. Differences in actual results and performance may arise as a
result of a number of factors including, without limitation, seasonality, the
timing of onset, length and severity of cold and flu seasons, the level of
success in executing on our strategic initiatives, our reliance on sales of
our influenza diagnostic tests, uncertainty surrounding the detection of novel
influenza viruses involving human specimens, our ability to develop new
products and technology, adverse changes in the competitive and economic
conditions in domestic and international markets, our reliance on and actions
of our major distributors, technological changes and uncertainty with research
and technology development, including any future molecular-based technology,
the medical reimbursement system currently in place and future changes to that
system, manufacturing and production delays or difficulties, adverse
regulatory actions or delays in product reviews by the U.S. Food and Drug
Administration(the "FDA"), compliance withFDAand environmental regulations,
our ability to meet unexpected increases in demand for our products, our
ability to execute our growth strategy, including the integration of new
companies or technologies, disruptions in the global capital and credit
markets, our ability to hire key personnel, intellectual property, product
liability, environmental or other litigation, potential required patent
license fee payments not currently reflected in our costs, adverse changes in
our international markets, potential inadequacy of booked reserves and
possible impairment of goodwill, and lower-than-anticipated acceptance, sales
or market penetration of our new products. Forward-looking statements
typically are identified by the use of terms such as "may," "will," "should,"
"might," "expect," "anticipate," "estimate," and similar words, although some
forward-looking statements are expressed differently. The risks described
under "Risk Factors" in reports and registration statements that we file with
theSecurities and Exchange Commission(SEC) from time to time should be
carefully considered. You are cautioned not to place undue reliance on these
forward-looking statements, which reflect management's analysis only as of the
date of this press release. We undertake no obligation to publicly release the
results of any revision or update of the forward-looking statements, except as
required by law.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Suzanne Clancy
858-205-4235 (mobile)

Quidel Contact:
Ruben Argueta

SOURCE Life Technologies Corporation; Quidel Corporation
Press spacebar to pause and continue. Press esc to stop.